Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

• Status: Unknown status
• Trial end date: 2020-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Ph-like ALL is a recently recognized high-risk subgroup and the optimal therapeutic approaches are poorly characterized. Based on the pediatric-inspired, PEG-L-asparaginase-intensified and MRD-directed PDT-ALL-2016 protocol, this open-label, two-arm, multi-site trial PDT-Ph-like-ALL is aimed to evaluate the safety and effect of oral histone deacetylase inhibitor chidamide and dasatinib for adult Ph-like ALL.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nanfang Hospital of Southern Medical University
• Treatments: 6-Mercaptopurine; Dasatinib; Histone Deacetylase Inhibitors

Criteria

Inclusion Criteria:

• 14-55 years old;

• Ph-like ALL newly diagnosed;

• signed written informed consent

Exclusion Criteria:

• Pregnant women;

• History of pancreatitis;

• History of diabetes;

• History of active peptic ulcer disease in the past 6 months;

• History of arteriovenous thrombosis in the past 6 months;

• Severe active infection;

• Allergic to any drugs in PDT-Ph-like-ALL.